The anti-HIV drug Dolutegravir improves outcomes for children with HIV infection, when given in a 3-drug anti-HIV combination. These results come from the ODYSSEY trial which was presented yesterday at the Conference on Retroviruses and Opportunistic Infections. Dolutegravir has a number of potential advantages, including: Few drug-to-drug interactions, making it easier to ...
Men who have had surgery for early stage testicular cancer can avoid potentially harmful scans.
Tribute to Professor James Hakim
PediCAP recruits its first participant
European Medicines Agency approves use of Dolutegravir 5 mg dispersible tablet for younger children living with HIV